Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.56 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.53 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.49 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.49 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23001085 | 1.00 | FABP3 (0.56) | FABP3P2RY10GPR34ALDH1A1LPAR1 | |
| SCHEMBL20472539 | 1.00 | FABP3 (0.56) | FABP3P2RY10GPR34ALDH1A1LPAR1 | |
| SCHEMBL9027639 | 1.00 | FABP3 (0.56) | FABP3P2RY10GPR34ALDH1A1LPAR1 | |
| SCHEMBL515226 | 1.00 | FABP3 (0.56) | FABP3P2RY10GPR34ALDH1A1LPAR1 | |
| SCHEMBL16180754 | 0.96 | FABP3 (0.53) | FABP3P2RY10GPR34ALDH1A1LPAR1 | |
| SCHEMBL5190825 | 0.92 | FABP3 (0.62) | FABP3P2RY10GPR34 | |
| SCHEMBL5475892 | 0.92 | FABP3 (0.62) | FABP3P2RY10GPR34 | |
| SCHEMBL1643923 | 0.92 | FABP3 (0.62) | FABP3P2RY10GPR34 | |
| SCHEMBL23166803 | 0.89 | ALDH1A1 (0.53) | FABP3ALDH1A1LPAR1ENPP2LPAR4 | |
| SCHEMBL23091273 | 0.89 | ALDH1A1 (0.53) | FABP3ALDH1A1LPAR1ENPP2LPAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20260053785-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | claimed |
| US-20250339680-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2025-11-06 | — | — | US | claimed |
| EP-4615431-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2025-09-17 | — | — | EP | claimed |
| EP-4604957-A1 | COMBINATIONS OF A SERD FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2025-08-27 | — | — | EP | claimed |
| US-20250205233-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS IN COMBINATION WITH AN AKT INHIBITOR FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-06-26 | — | — | US | claimed |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE | 2025-05-29 | — | — | US | claimed |
| WO-2025083205-A1 | DRUG COMBINATION COMPRISING ANTI-CD37 ANTIBODY MAYTANSINE CONJUGATE AND BCL2 INHIBITOR OR PI3K INHIBITOR | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-04-24 | — | — | WO | claimed |
| EP-4519418-A1 | METHODS FOR IMPROVING T CELL EFFICACY | Immatics US, Inc. (US) | 2025-03-12 | — | — | EP | claimed |
| WO-2007071658-A2 | ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF | ÆTERNA ZENTARIS GMBH (DE) | 2007-06-28 | — | — | WO | claimed |
| EP-1800684-A1 | Novel alkyl phospholipid derivatives and uses thereof | Zentaris GmbH (DE) | 2007-06-27 | — | — | EP | claimed |
| WO-2006121518-A2 | ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | claimed |
| WO-2006121522-A2 | IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | claimed |
| WO-2006118630-A2 | PHOSPHOINOSITIDE MODULATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-11-09 | — | — | WO | claimed |
| US-20050165245-A1 | Phospholipid-analogous compounds | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2005-07-28 | — | — | US | claimed |
| US-20030083313-A1 | Treatment of breast cancer with a liposome mixture comprising an antineoplastic alkylphospholipid and water- or lipid-soluble antiestrogen agents | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2003-05-01 | — | — | US | claimed |
| EP-1135193-B1 | AGENTS PROVIDED FOR TREATING TUMORS, BASED ON LIPOSOMES, AND CONTAINING TAMOXIFEN | MAX DELBRUECK CENTRUM (DE) | 2002-10-30 | — | — | EP | claimed |
| EP-0507337-B1 | Novel erucyl, brassidyl and nervonyl derivatives | MAX PLANCK GESELLSCHAFT (DE) | 1996-10-23 | — | — | EP | claimed |
| US-5436234-A | Treatment of protozoal and fungal diseases, autoimmune diseases and bone marrow damage | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG (DE) | 1995-07-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053785-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, PI4K2A, PIK3CA | FABP3 4729/4885P2RY10 2306/4885GPR34 2386/4885 |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | FABP3 1079/4885P2RY10 4866/4885GPR34 3993/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | FABP3 3902/4885P2RY10 2300/4885GPR34 4212/4885 |
| US-20250205233-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS IN COMBINATION WITH AN AKT INHIBITOR FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | FABP3 2973/4885P2RY10 4596/4885GPR34 2687/4885 |
| US-20050165245-A1 | Phospholipid-analogous compounds | PHOSPHO1, SGMS1, SGMS2 | FABP3 910/4885P2RY10 678/4885GPR34 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.